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Background: Malaria is a deadly infectious disease affecting millions of people in tropical and sub-tropical countries.
Among the five species of Plasmodium parasites that infect humans, Plasmodium falciparum accounts for the highest
morbidity and mortality associated with malaria. Since humans are the only natural hosts for P. falciparum, the lack of
convenient animal models has hindered the understanding of disease pathogenesis and prompted the need of testing
anti-malarial drugs and vaccines directly in human trials. Humanized mice hosting human cells represent new
pre-clinical models for infectious diseases that affect only humans. In this study, the ability of human-immune-system
humanized HLA-DR4.RagKO.IL2RγcKO.NOD (DRAG) mice to sustain infection with P. falciparum was explored.
Methods: Four week-old DRAG mice were infused with HLA-matched human haematopoietic stem cells (HSC) and
examined for reconstitution of human liver cells and erythrocytes. Upon challenge with infectious P. falciparum
sporozoites (NF54 strain) humanized DRAG mice were examined for liver stage infection, blood stage infection, and
transmission to Anopheles stephensi mosquitoes.
Results: Humanized DRAG mice reconstituted human hepatocytes, Kupffer cells, liver endothelial cells, and
erythrocytes. Upon intravenous challenge with P. falciparum sporozoites, DRAG mice sustained liver to blood stage
infection (average 3–5 parasites/microlitre blood) and allowed transmission to An. stephensi mosquitoes. Infected DRAG
mice elicited antibody and cellular responses to the blood stage parasites and self-cured the infection by day 45
post-challenge.
Conclusions: DRAG mice represent the first human-immune-system humanized mouse model that sustains the
complex vertebrate life cycle of P. falciparum without the need of exogenous injection of human hepatocytes/
erythrocytes or P. falciparum parasite adaptation. The ability of DRAG mice to elicit specific human immune
responses to P. falciparum parasites may help deciphering immune correlates of protection and to identify
protective malaria antigens.
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Malaria infection is initiated by the bite of an infected
female Anopheles mosquito and inoculation of sporo-
zoites in the skin that rapidly migrate through the
bloodstream to infect hepatocytes. Mature liver stage
parasites are then released to the bloodstream to
invade red blood cells (RBCs) and to initiate the asexual
erythrocytic cycles responsible for the clinical manifesta-
tions of malaria [1]. Among the five species of Plasmodium
that infect humans, Plasmodium falciparum is the
most virulent with 1.2 billion people at high risk. The
number of P. falciparum deaths reported by WHO for
2012 was 627,000, while the Institute of Health Metrics
and Evaluation reported 1.24 million deaths for 2010
[2], the same year when WHO reported 655,000
deaths. Malaria is a disease of poverty and a cause of
poverty as it has deeply slowed economic growth in
malaria endemic areas. The current rise of earth
temperature could hasten mosquito breeding at higher
altitudes and latitudes and might increase the burden
of malaria across the globe [3].
Since humans are the only species that can be natur-
ally infected with P. falciparum, the development of
efficacious malaria vaccines and anti-malarial drugs has
been hindered by the lack of convenient animal models.
The ability of great apes (chimpanzees, gorillas and
bonobos) to sustain P. falciparum natural infection is
controversial, though they develop malaria upon experi-
mental challenge with sporozoites [4,5]. The use of great
apes for biomedical research is currently under mora-
torium [6]. New World monkeys are susceptible to
experimental infection with P. falciparum blood stage
parasites that have been previously adapted to grow in
monkeys, and splenectomy is vital for maintenance of
long-term infections [7]. Except for one Aotus strain
(Aotus lemurinus griseimembra), New World monkeys
do not sustain reproducible P. falciparum liver stage
infection [7], which further poses a challenge for testing
pre-erythrocytic drugs and vaccines. Studies in rodent
models of malaria have significantly advanced our
understanding of the parasite biology but it has become
clear that rodent malaria does not represent the
complexity of P. falciparum and that vaccines that were
able to protect mice against murine parasites did not
protect humans against P. falciparum when tested in
clinical trials. There are relevant differences between
rodent malaria parasites and P. falciparum. The
duration of liver stage infection is two days for rodent
malaria parasites, but 5–7 days for P. falciparum [8].
Some antigenic proteins expressed by P. falciparum-in-
fected hepatocytes or infected RBCs do not have
orthologs for rodent malaria parasites, as is the case of
liver stage antigen 1 (LSA1) [9] and the polymorphic
or “variant” proteins encoded by var, rif, stevor, andPfmc-2TM, which are responsible for immune evasion
[1]. Some proteins shared by P. falciparum and
rodent malaria parasites do not exert the same
biological function [10]. Though P. falciparum sporozo-
ites do not invade and develop in mouse hepatocytes
[11,12], mice are often used to assess the immunogen-
icity of P. falciparum pre-erythrocytic sub-unit vaccine
candidates, particularly for the circumsporozoite pro-
tein (CSP), which is highly expressed on sporozoites.
This approach is however challenged by the differential
ability of mouse Major Histocompatibility Complex
(MHC) vs human MHC (HLA) molecules to present
malaria T cell epitopes, which may drive different
cellular and humoral responses to P. falciparum anti-
gens [13].
To overcome these limitations much effort has been
devoted to generate humanized mouse models for P.
falciparum. Immunodeficient mice transgenic for
urokinase-type plasminogen activator transgene (uPa,
SCID/ uPa mice) or knockout for fumarylacetoacetate
hydrolase (Fah, FRG mice) transplanted with human
hepatocytes have proven to sustain P. falciparum liver
stage infection [11,14,15] and to transition toward
blood stage infection upon exogenous injection of
human erythrocytes [11]. Likewise, immunodeficient
mice injected daily with very large numbers of human
RBCs can sustain P. falciparum blood stage infection
upon challenge with P. falciparum mouse-adapted
blood stage parasites but only for a short period of
time, since the human RBCs rapidly disappear from
blood circulation upon cessation of RBC daily injections
[16-20]. The lack of a human-immune-system in these
models also prevents investigating human immune
responses to P. falciparum.
Human-immune-system (HIS) humanized mice rep-
resent new pre-clinical models for human infectious
diseases and for testing human vaccines. Studies
demonstrated that expression of HLA class II mole-
cules on HIS mice favors human haematopoietic stem
cell (HSC) engraftment, human T cell development,
and human B cell immunoglobulin class switching
[21,22]. One of these models, namely DRAG (HLA-
DR4.RagKO.IL2RγcKO.NOD) mice, when infused with
HLA II-matched human HSC, develop functional
human T and B cells, reconstitute serum levels of all
human immunoglobulin classes and subclasses (natural
antibodies), and respond to vaccination by eliciting spe-
cific antibodies [21]. This study demonstrates that human-
ized DRAG mice also reconstitute human hepatocytes,
Kupffer cells, liver endothelial cells, and erythrocytes/re-
ticulocytes, and sustain the full vertebrate life cycle of P.
falciparum. Infected DRAG mice elicited specific antibody
and cellular responses and self-cured the infection by day
45 after the challenge.
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Mice
Animal procedures reported herein were conducted
under protocols approved by the Institutional Animal
Care and Use Committees at the Walter Reed Army
Institute of Research/Naval Medical Research Center
and at the Uniformed Services University of Health
Sciences in compliance with the Animal Welfare Act
and in accordance with the principles set forth in the
“Guide for the Care and Use of Laboratory Animals,”
Institute of Laboratory Animals Resources, National
Research Council, National Academy Press, 1996. The
HLA-DR4.Rag1KO.IL2RγcKO.NOD (DRAG) mice were
bred at NMRC/WRAIR Veterinary Service Program.
Procedures for infusion of HLA-DRB1*0401-positive
human HSC from umbilical cord blood have been pre-
viously described [21]. DRAG mice were used at four
months post-infusion of human HSC.
Immunohistochemistry
Livers were separated into lobes, embedded in Tissue-
tek O.C.T. compound (Sakura Finetek, Torrance, CA)
and immediately frozen at −80°C. Serial 8-μm cryo-
sections were stored at −80°C until use. Slides were
thawed for 30 min at room temperature and fixed
either with cold absolute methanol for 10 min followed
by cold acetone for 1 min (for hepatocyte and liver-
stage parasite immunostaining) or with BD Cytofix/
Cytoperm fixation/permeabilization kit (for Kupffer cell
and endothelial cell immunostaining). Following fix-
ation, sections were washed three times with PBS,
blocked with PBS/1% BSA for 30 min at 37°C, washed
again and incubated with primary antibodies for 30 min
at 37°C, washed again and incubated with secondary
antibodies for 30 min at 37°C. The primary antibodies
used were mouse anti-human hepatocyte specific anti-
gen (Hep Par-1, clone #OCH1E5, Santa Cruz Biotech-
nology, Dallas, TX), mouse anti-human CD68 (clone
#Y1/82A, BDbiosciences,), mouse anti-human CD36
(clone #CB38, BDbiosciences,) or rabbit anti-P. falciparum
heat shock protein 70 (PfHSP70) antibody (LifeSpan Bio-
sciences, Seattle, WA). Secondary antibodies were FITC-
goat anti-rabbit IgG (H + L) (KPL, Gaithersburg, MD),
Rhodamine goat anti-mouse IgG (H + L) (KPL), FITC-
goat anti-mouse IgG2b (Southern Biotech, Birmingham,
AL), and FITC-goat anti-mouse IgM (Southern Biotech).
Slides were washed, air dried, and mounted in Vectashield
mounting medium with DAPI (Vector Laboratories,
Burlingame, CA). Thin blood smears were fixed with
0.05% glutaraldehyde and permeabilized with 0.1%
Triton-X100, blocked with PBS/1% BSA for 30 min at
RT, and stained with mouse anti-human haemoglobin
A (Ray Biotech, Norcross, GA) followed by anti-mouse
IgG1-FITC (Southern Biotech). Slides were examinedunder fluorescence microscopy (wide-field for hepatocytes,
Kupffer cells and endothelial cells or confocal for liver stage
malaria parasites). Wide-field fluorescence images were
acquired using QCapture Pro 6.0 software in Olympus
BX51 microscope and confocal images were acquired using
LaserSharp2000 software in Zeiss/Bio Rad Laser Confocal
Microscope. For human transferrin staining, sections from
10% formalin fixed, paraffin-embedded livers were sub-
jected to antigen-retrieval, stained with anti-human trans-
ferrin (Histoserv, Germantown, MD), and examined under
light microscopy.Isolation of spleen cells, bone marrow cells, hepatocytes
and Kupffer cells
Splenic and bone marrow cells were isolated as
described [21]. Livers were perfused as described [23]
using liver perfusion medium (Life Technologies, Grand
Island, NY) followed by liver digest medium (0.8 mg/
mL collagenase type I in DMEM). Liver cells were
suspended in wash solution (2% BSA/10 mM Hepes/
2 mM EDTA/2 mM β mercaptoethanol/DMEM), passed
through 100-micron cell strainers and washed three
times at 50 g for 2 min to pellet hepatocytes. Following
each wash, the supernatants were collected, spun at
1350 g for 10 min, cell pellets were combined and
washed thrice with wash solution to collect the cell
fraction containing Kupffer cells.FACS analysis
Kupffer cells were washed with PBS/1% BSA/0.1%
NA azide (staining buffer), blocked with Fc block
(BDbiosciences, San Jose, CA) for 10 min on ice,
incubated with anti-human CD45 (BDbiosciences)
for 30 min, followed by intra-cellular staining with
anti-human CD68 (clone# Ki-M7, AbD serotec,
Raleigh, NC) using BD Cytofix/Cytoperm fixation/
permeabilization kits (BDbiosciences). Hepatocytes
were washed with staining buffer followed by intra-
cellular staining with goat anti-human serum albu-
min (MyBiosource, San Diego, CA). Approximately
5 million events were acquired for each staining.
Peripheral blood (1–2 μl) drawn from the vein of the tail
was collected in heparin-coated capillaries (Sigma-Aldrich,
St Louis, MO), washed twice with PBS, suspended in PBS/
1% BSA, blocked with Fc Block for 15 minutes at RT and
stained with anti-human CD235 (BDbiosciences) and
Retic-Count (BDbiosciences) for 30 minutes. Bone
marrow cells were obtained by flushing both tibias as de-
scribed [21] and cell surface stained with anti-human
CD45, anti-human CD71, anti-human CD235, and anti-
mouse Ter-119 antibodies (BDbiosciences). Apoptosis in
bone marrow cells was measured using Annexin V/7-
ADD apoptosis detection kit (BD Biosciences).
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Peripheral blood was drawn from the tail vein in heparin-
coated capillaries and plasma was collected following
centrifugation. Plasma levels of human transferrin were
measured using anti-human transferrin ELISA kits (Bethyl
Laboratories, Montgomery, TX).
Plasmodium falciparum parasites
Plasmodium falciparum (NF54 or 3D7)-infected
Anopheles stephensi mosquitoes were obtained from the
Department of Entomology, WRAIR/NMRC. Infectious
P. falciparum sporozoites were isolated by dissecting the
salivary glands in E-199 medium (Quality Biological,
Gaithersburg, MD) with 5% human AB serum (Key Bio-
logics, Memphis, TN). Mice were challenged intraven-
ously with P. falciparum sporozoites and followed for
parasitaemia by PCR and thin and thick Giemsa-stained
blood smears.
Detection of malaria parasites by PCR
Mice were bled from the tail vein and DNA was
extracted using DNeasy blood and tissue kits (Qiagen,
Valencia, CA). A pair of Plasmodium genus-specific
primers [24] was used to amplify all units of rRNA
distributed in chromosomes 1, 5, 7, 11 and 13; Forward 5-
GCTCTTTCTTGATTTCTTGGATG-3 Reverse 5-AG
CAGGTTAAGATCTCGTTCG-3. PCR amplification was
carried out in 20 μL reaction volume containing 50 ng
of test or positive control DNA, 0.025 unit of Taq
polymerase (Life technologies), 0.5 μM each of primers,
0.2 mM deoxynucleotide triphophates (dNTPs) (Life
technologies) and 0.2 mM MgCl2. PCR settings were:
1 cycle for 95°C for 10 min followed by 41 cycles of
95°C for 30 sec, 56°C for 30 sec and 72°C for 1 min.
PCR amplified products were analysed on agarose gels
(3%) with ethidium bromide.
In vitro culture of P. falciparum parasites and mosquito
feeding
DRAG mice challenged with P. falciparum sporozoites
were bled on day 14 and 18 post-challenge and 20–
50 μl of blood was cultured with 5% haematocrit (O+
human RBCs) (Key Biologics) in RPMI 1640 supple-
mented with 2 mM L-glutamine (Life technologies),
25 mM Hepes, 0.36 mM hypoxanthine, 2 g/L sodium
bicarbonate and 10% human AB serum (Key Biologics)
at 37°C in a mixture of gas containing 5% CO2, 5% O2,
and 90% N2. Asexual blood cultures were maintained
with daily media changes and weekly subcultures in O+
human erythrocytes. Parasitaemia in cultures was
examined by Giemsa-stained thick and thin blood
smears. At 2% asexual parasitaemia, cultures were sub-
cultured in fresh O+ human RBCs and maintained with
daily media changes until the development of maturegametocytes. At 1.8-2.0% gametocytaemia, cultures were
spun at 500 g for 10 min, the parasite pellet was re-
suspended in 2 mL of human A+ serum with 0.5 mL of
packed O+ human RBCs and starved female An. stephensi
mosquitoes were fed on the gametocyte suspension using
membrane feeders (in vitro feeding). For in vivo feeding,
An. stephensi mosquitoes were allowed to feed on for five
minutes on infected mice anaesthetized with ketamine.
Unfed mosquitoes were removed and the fed mosquitoes
were maintained at the Department of Entomology,
WRAIR/NMRC. Midguts and salivary glands were
dissected at day 7 and 14 post-feeding to determine the
percentage of mosquitoes infected with oocysts and
sporozoites.
Plasmodium falciparum antibody titers by
immunofluorescence Assay (IFA)
Teflon printed 12-well slides (Electron Microscopy Sci-
ences, Hatfield, PA) were coated either with synchronized
P. falciparum ring-stage parasite infected-red blood cells
(iRBC) [25] or trophozoite/schizont infected RBCs [26]
(6,000 RBCs/well at 6% parasitaemia, in PBS/1% BSA).
Slides were air dried and stored at −80°C until use. Upon
thawing, slides were blocked with PBS/1% BSA for 30 min
at 37°C. Twenty microlitres of plasma at various dilutions
was added to the wells and incubated for 1 h at 37°C.
Slides were washed three times with PBS, incubated
with FITC-labeled anti-human IgG or IgM (Southern
Biotech) for 30 min at 37°C, washed, and mounted with
Vectashield-DAPI (Vector Laboratories).
T cell responses
Cultures of P. falciparum blood stage parasites (NF54, 108,
5% parasitaemia) were pelleted and suspended in ACK
(Invitrogen) for five minutes in ice to lyse the erythrocytes,
washed twice in 1xPBS and the parasite pellet was freeze-
thawed three times using liquid nitrogen and boiling water,
followed by sonication at 75% amplitude, with 20 sec on,
10 sec off for 3 min. Cell lysates were centrifuged at
10,000 rpm/4°C for 15–20 min and protein concentration
was measured by Biuret. Splenocytes (5x105) were stimu-
lated with P. falciparum proteins extracts (30 μg/ml) for
2 days or left unstimulated. In vitro-stimulated cells were
incubated with Golgistop (BDbiosciences) for four hours,
surface stained with human CD3, CD4 and CD8 antibodies
and intracellularly stained with human TNF and IFNγ and
analysed by FACS.
Results
DRAG mice reconstitute human hepatocytes, Kupffer
cells, and liver endothelial cells
The ability of human HSC (CD34+) to differentiate into
non-haematopoietic cells such as hepatocytes, cardio-
myocytes, and endothelial cells has become evident in
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whether DRAG mice develop human hepatocytes by
measuring plasma levels of human transferrin, a protein
secreted by human hepatocytes [28]. At 14 weeks post-
infusion of human HSCs the levels of human transferrin
averaged 2–3 ng/ml (Figure 1A, left panel), which is about
5x105 fold lower than the levels of transferrin in human
plasma (1 mg/ml) [28]. No human transferrin was
detected in plasma of naïve (non-HSC infused) DRAG
mice. Longitudinal analysis indicated that DRAG mice
reconstituted human transferrin at eight weeks post-
infusion of HSCs and the levels remained constant for up
to 22 weeks (Figure 1A, right panel). Histological examin-
ation using anti-human transferrin (Figure 1B) and anti-
human Hep Par-1 (a marker specific for humanFigure 1 DRAG mice develop human hepatocytes. A) Plasma levels of h
No human transferrin was detected in serum from control (non-HSC infused) D
(left panel). Kinetics of human transferrin in plasma of two DRAG mice analyse
transferrin. Arrow shows the presence of human hepatocytes. C) Identification o
anti-Hep Par-1 (red) and counterstained with DAPI (DNA, blue). D) Frequency o
anti-human albumin. Left panel shows binding of anti-human albumin to prima
(white histogram). Middle and right panels show anti-human albumin staining i
respectively. Data represent mean and interval frequencies from three mice anahepatocyte mitochondria) [29] (Figure 1C) revealed the
presence of scattered human hepatocytes within the livers.
To estimate the frequency of human hepatocytes, livers of
HSC-infused DRAG mice were analysed by FACS using
anti-human albumin. As illustrated in Figure 1D, approxi-
mately 0.023% of the hepatocytes in mouse livers were of
human origin. Thus the results indicated that DRAG mice
infused with HSC develop human hepatocytes.
Prior to infection of hepatocytes, sporozoites must
cross the sinusoidal cell layer and interact with endothe-
lial cells and Kupffer cells [30,31]. The presence of
human Kupffer cells in livers of HSC-infused DRAG was
revealed by immunohistochemistry using anti-human
CD68 (Figure 2A). CD68 is a glycoprotein binding to
low density lipoprotein (LDL) expressed on matureuman transferrin in DRAG mice (n = 14) at 14 weeks post-infusion of HSC.
RAG mice (n = 7). Data represent mean ± SD of mice analysed individually
d individually (right panel). B) Staining of liver sections with anti-human
f human hepatocytes in livers of HSC-infused DRAG mice using human
f human hepatocytes in livers of DRAG mice as measured by FACS using
ry human hepatocytes (black histogram) but not to mouse hepatocytes
n livers of control (non-HSC infused) and in HSC-infused DRAG mice,
lysed individually.
Figure 2 DRAG mice develop human Kupffer cells and liver endothelial cells. A) Immunostaining of livers using anti-human CD68 (green
fluorescence) and counterstained with DAPI (DNA, blue fluorescence). B) Frequency of human Kupffer cells in livers of DRAG mice as determined
by FACS using anti-human CD45 and anti-human CD68 on cells gated on the FSC/SSC monocyte region. Middle and right panels show CD68
staining on human (gated CD45+) cells and mouse (gated CD45−) cells isolated from livers of HSC-infused DRAG mice. Data represent mean and
interval frequencies from 4 mice analysed individually. Left panel shows binding of anti-human CD68 to monocytes from human peripheral
blood. C) Immunostaining of livers using anti-human CD36 and counterstained with DAPI (DNA, blue fluorescence) showing presence of human
endothelial cells in veins and sinusoids.
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the frequency of human Kupffer cells, mononuclear cells
isolated from livers that had been previously perfused to
remove circulating blood cells, were analysed by FACS
using anti-human CD45 (a marker expressed on human
haematopoietic cells) [22] and anti-human CD68. As illus-
trated in Figure 2B (middle panel), the frequency of Kupffer
cells (CD68+CD45+) averaged 11%. The specificity of the
anti-human CD68 is shown by binding to monocytes from
human peripheral blood (Figure 2B left panel) but not to
mouse (CD45−) cells from livers of HSC-infused DRAG
mice (right panel). Livers from HSC-infused DRAG mice
also showed the presence of human endothelial cells lining
the sinusoids, as indicated by histological examination
using anti-human CD36 (Figure 2C). In aggregate, the re-
sults indicated that HSC-infused DRAG mice develop hu-
man hepatocytes, Kupffer cells, and liver endothelial cells.DRAG mice reconstitute human erythrocytes
RBC precursors from the bone marrow are released to
the peripheral blood as reticulocytes (immature RBCs),
which differentiate toward erythrocytes (mature RBCs)
within 1–4 days of blood circulation [33]. Peripheral blood
from HSC-infused DRAG mice was examined by FACS
using anti-human CD235a (glycophorin A) and Retic-
Count to estimate the frequency of human reticulocytes
(CD235a+/Retic-Count+) and erythrocytes (CD235a+/Retic-
Count−). Retic-Count is a solution of thiazole orange that
binds to ribosomal and mitochondrial RNA present in
reticulocytes but absent in erythrocytes [34]. As illustrated
in Figure 3A, human reticulocytes and erythrocytes were
present in blood of HSC-infused DRAG mice, but not
in control (non-infused) DRAG mice. Interestingly, the
pattern of CD235a expression in human erythrocytes and
reticulocytes of DRAG mice was similar to that of human
Figure 3 DRAG mice infused with human HSC develop human RBCs. A) Enumeration of human erythrocytes (hEry) and reticulocytes (hRet)
in peripheral blood of DRAG mice by FACS using anti-human CD235a (glycophorin A) and Retic-Count (left panel). Controls are DRAG mice
non-infused with HSCs (upper right panel) and human blood (lower right panel). B) Immunostaining of peripheral blood from HSC-infused DRAG
mice (right) and human blood (left) with anti-human haemoglobin A. Arrow shows the presence of human RBCs. C) Frequency of human
erythrocytes and reticulocytes in blood of HSC-infused DRAG mice (n = 10). Data represent mean ± SD of mice analysed individually. D) Bone
marrow from HSC-infused (n = 3) and control (non-infused) (n = 7) DRAG mice was stained with anti-human CD235a and anti-mouse Ter-119
(upper left panels). Data represent mean ± SD of mice analysed individually. Staining with anti-human CD235a and anti-human CD71 showed that
that the nucleated human RBC precursors expressed CD71 (upper right panel) (n = 1). Annexin-V and 7-AAD staining of human RBC precursors
(CD235+) and non-erythroctyc precursors (CD235−) in the bone marrow of HSC-infused DRAG mice (lower panels) (n = 1).
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expressed higher levels of CD235a than the erythrocytes.
Human RBCs in the peripheral blood of HSC-infused
DRAG mice were also visualized by immunohistochemistry
using anti-human haemoglobin A (Figure 3B).
Human RBCs in the blood of DRAG mice were de-
tected for up four-months after infusion of human
HSCs, though the human haematocrit only represented
0.2-1% of the total haematocrit (Figure 3C). To determine
whether the low human haematocrit in DRAG mice was
due to insufficient differentiation of human HSC toward
the erythrocytic lineage (erythropoiesis), the bone marrow
was examined by FACS. As illustrated in Figure 3D (upper
left panels), the frequency of human RBCs precursors(CD235a+) was significantly lower than the frequency of
mouse RBC precursors (Ter-199+), despite a high fre-
quency of human cells (CD45+, 45 ± 16%) and human
HSC (CD45+CD34+, 4.7 ± 0.7%) in the bone marrow. The
human RBC precursors in bone marrow expressed human
CD71 (transferrin receptor) (Figure 3D, upper right panel),
a marker expressed by nucleated human RBC precursors
that is lost after enucleation and differentiation toward re-
ticulocytes and erythrocytes [35].
To determine whether the human RBC precursors
could have been eliminated by apoptosis, the bone
marrow of HSC-infused DRAG mice was stained
with Annexin V and 7-AAD (markers for early and
late apoptosis) and human CD235. As illustrated in
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(CD235+) showed minimal apoptosis and comparable
to that of non-erythrocytic (CD235−) cells, which ar-
gues against the human erythrocytic precursors being
deleted by apoptosis. The results thus indicated that
the low frequency of human RBCs in the blood of
DRAG mice accounts for insufficient differentiation
of human HSCs toward the erythrocytic lineage.
DRAG mice challenged with P. falciparum sporozoites
develop blood stage parasitaemia and are infectious to
Anopheles stephensi mosquitoes
Since DRAG mice develop human hepatocytes, Kupffer
cells, endothelial cells, and erythrocytes, it was next
investigated whether they sustain the vertebrate life
cycle of P. falciparum. For this, DRAG mice were
challenged i.v. with P. falciparum sporozoites (NF54,
105 per mouse) and five days later the livers were ex-
amined by immunohistochemistry using anti-P. falcip-
arum HSP70 (PfHSP70). Plasmodium falciparum liver
stage schizonts were detected in the livers (Figure 4A),Figure 4 DRAG mice sustain the complete vertebrate life cycle of P. fa
105 infectious P. falciparum sporozoites and five days later the livers were staine
microscopy. Data show a representative P. falciparum liver stage schizont. Scale
and followed for blood stage parasitaemia by PCR using primers specific for Pla
from five independent challenges. C) PCR analysis in a group of four HSC-infuse
control; M, DNA molecular markers. D) Giemsa staining of thick (upper panel) an
the presence of P. falciparum rings in thick smears and trophozoites in thin smewhich demonstrated that human hepatocytes developed
by DRAG mice sustain infection by P. falciparum
sporozoites.
To determine whether the liver stage parasites can tran-
sition toward blood stage parasites, additional groups of
DRAG mice were challenged with P. falciparum sporozo-
ites as above and they were follow-up for blood stage
parasitaemia. As illustrated in Figure 4B and C, all
DRAG mice challenged with NF54 P. falciparum sporo-
zoites (a total of 31 mice from five independent
challenges) developed blood stage parasitaemia as
measured by PCR with a pre-patent period ranging
between 10 to 28 days post-challenge. As measured by
Giemsa-stained blood smears the levels of parasitaemia
were low (3–5 parasites/μl of blood) (Figure 4D), which
is explained by the low level of human haematocrit
developed by DRAG mice (Figure 3C). DRAG mice (n = 4)
challenged with sporozoites of P. falciparum strain 3D7
also became parasitaemic by day 17 post-challenge, which
indicated that DRAG mice also sustain the vertebrate life
cycle of 3D7 malaria parasites.lciparum infection. A) HSC-infused DRAG mice were challenged i.v. with
d with anti-PfHSP70 (green) and DAPI (DNA, blue) and analysed by confocal
bars are 10 μm. B) DRAG mice were challenged with sporozoites as above
smodium 18S rRNA. Data show percentage of parasitaemic mice (n = 31)
d DRAG mice at day 28 post-challenge. NC, negative control; PC, positive
d thin (lower panel) blood smears from infected DRAG mice. Arrows show
ars.
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http://www.malariajournal.com/content/13/1/386Plasmodium falciparum blood stage parasites from the
peripheral blood of infected DRAG mice expanded upon
in vitro culture. Figure 5A (left and middle panels) shows
the presence of P. falciparum rings (r), trophozoites (t),
and schizonts (s) in the in vitro cultures. The asexual
blood stage parasites differentiated into gametocytes (g)
(Figure 5A, right panel), and developed into oocysts and
sporozoites in An. stephensi mosquitoes fed on the
gametocyte cultures (Figure 5B). Anopheles stephensi mos-
quitoes directly fed on infected DRAG mice (day 28 post-
challenge) also developed oocysts and sporozoites
(Figure 5B and C). In aggregate these results indicated that
DRAG mice sustain the complex vertebrate life cycle of P.
falciparum.
DRAG mice elicit immune responses to P. falciparum
blood stage parasites and self-cure the infection
Longitudinal analysis in additional groups of DRAG
mice (n = 18) revealed that all mice self-cured by day
45 post-challenge with sporozoites (Figure 6A). Since
antibodies and cytotoxic cytokines play a role in theFigure 5 Plasmodium falciparum blood stage parasites from infected
in vitro cultures showing presence of rings (r), trophozoites (t) and schizont
Anopheles stephensi mosquitoes were fed on the gametocyte cultures (four
mouse (day 28 post-challenge). Oocysts in midgut and sporozoites in saliva
Data represent frequency of infected mosquitoes among 25–35 mosquitoe
infected DRAG mouse.clearance of blood stage parasites [36,37], and DRAG
mice develop a functional human immune system [21]
it was next investigated whether infected DRAG mice
could have elicited cellular and antibody responses to
P. falciparum blood stage parasites. Splenic human
CD4 and CD8 T cells from infected DRAG mice (day
28 post-challenge, n = 3) that were stimulated in vitro
with protein extracts of P. falciparum infected red
blood cells (Pf-iRBCs) produced TNF, but not IFNγ as
measured by FACS (Figure 6B). In addition, most
DRAG mice (14 out of 18) examined at day 28 post-
challenge elicited specific human IgM and IgG anti-
bodies, as measured by IFA using slides coated with P.
falciparum synchronized rings and trophozoites/schiz-
onts (Figure 6C). The IFA staining pattern of anti-
bodies to P. falciparum rings and trophozoites/
schizonts was consistent among the individual DRAG
mice (Figure 7). The results indicating that DRAG
mice elicited specific cellular and antibody responses
might thus account for their ability to clear P. falciparum
blood stage infection.DRAG mice expand in in vitro cultures. A) Giemsa staining of
s (s) (left and middle panels) and gametocytes (right panel). B)
independent membrane feedings) or directly on an infected DRAG
ry glands were examined at days 7 and 14 post-feeding, respectively.
s analysed individually. C) Oocysts in midgut of mosquitoes fed on an
Figure 6 Plasmodium falciparum-infected DRAG mice elicit specific antibodies and self-cure blood stage infection. A) DRAG mice (n = 18)
were challenged with P. falciparum sporozoites as in Figure 4 and followed for blood stage parasitaemia by PCR and blood smears. All mice were
infected by day 28 post-challenge but mice self-cured the infection by day 45 post-challenge. B) Spleen cells from infected DRAG mice (day 28
post-challenge) were stimulated in vitro with protein extracts of P. falciparum infected red blood cells (Pf-iRBCs) for 2 days or left unstimulated
and analysed by FACS using anti-human CD3, CD4, CD8, TNF, and IFNγ. Numbers on the histograms represent frequencies of TNF and IFNγ
positive cells among gated human CD4 and CD8 T cells from pooled mice (n = 3). C) Titers of human IgM (left panel) and IgG (right panel)
antibodies to Pf-iRBCs using IFA slides coated with synchronized rings and trophozoites/schizonts. Data represent antibody titers in mice analysed
individually at day 28 post-challenge. Fourteen out of 18 infected DRAG mice (closed circles) elicited specific antibodies, whereas uninfected
DRAG mice (n = 5) did not have specific antibodies (open circles).
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This study provides evidence for the first humanized
mouse model sustaining the complete life cycle of P.
falciparum (strains NF54 and 3D7). Humanized
DRAG mice infused with human HSCs developed
human hepatocytes, Kupffer cells, liver endothelial cells,
and erythrocytes and upon challenge with P. falciparum
sporozoites sustained liver-to-blood stages of infection and
supported transmission to An. stephensi mosquitoes. In the
SCID/uPA and FRG mice it has only been demonstrated
that the infused human hepatocytes can be infected with P.
falciparum sporozoites that mature and can infect exogen-
ously injected human RBCs [11]. Likewise, NSG mice have
only demonstrated P. falciparum blood stage infectionusing mouse adapted parasite strains as long as mice were
injected with human RBCs [16,17].
Unlike other humanized mouse models such as NSG,
DRAG mice express HLA class II molecules, and previous
studies demonstrated that expression of HLA class-II mol-
ecules in humanized mice is critical for reconstitution of
human T and B cells and immunoglobulin class switching
[21,38]. The ability of DRAG mice to develop human
hepatocytes seems to be unrelated to HLA-II expression
since prior studies in NSG mice (which do not express
human HLA-II molecules) showed development of
human hepatocytes from human HSCs. However there is
controversy on whether transdifferentiation of human
HSC into hepatocytes or cell fusion between human HSC
Figure 7 Representative IFA staining pattern of P. falciparum antibodies elicited by DRAG mice. Staining of P. falciparum synchronized rings
(A) and trophozoites/schizonts (B) with sera from infected DRAG mice and revealed with anti-human IgM (green) or IgG (green) and counterstained
with DAPI (DNA, blue). Giemsa staining of synchronized rings and trophozoites/schizonts in cultures is shown in left panels.
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human hepatocytes in humanized mice [39]. This study
shows for the first time that that hepatocytes developed
from HSCs sustain infection by P. falciparum sporozoites.
Despite the low numbers of human hepatocytes
developed by DRAG mice, all DRAG mice challenged
with sporozoites (n = 49) sustained liver stage infection,
since they developed blood stage parasitaemia (Figures 4B
and 6A). The high susceptibility of DRAG mice to liver
stage infection might relate to their ability to develop
human Kupffer cells and liver endothelial cells, which play
a critical role for recruitment of sporozoites to the liver
and infection of hepatocytes. Studies by Frevert’s group in
rodent models indicated that sporozoite infection of the
liver involves three steps: arrest in the sinusoid by inter-
action with endothelial cells, gliding to and passage
through Kupffer cells, and invasion of hepatocytes [30].
Other authors however have found a minimal role of
sporozoite traversal of Kupffer cells, but a role of sporozo-
ite traversal of liver endothelial cells for effective infection
of hepatocytes [31]. The need of accessory (Kupffer and/
or endothelial) cells for effective sporozoite infection of
hepatocytes has also became evident in in vitro studies,
since cultures of isolated human hepatocytes (devoid of
Kupffer and endothelial cells) have a very low rate of
infection [40]. The ability of DRAG mice to reconstitute
human Kupffer and liver endothelial cells may thusaccount for their high susceptibility to P. falciparum liver
stage infection, despite the low numbers of human
hepatocytes.
DRAG mice challenged with P. falciparum sporozoites
developed blood stage parasitaemia and supported trans-
mission to An. stephensi mosquitoes. The low level
human haematocrit and hence parasitaemia in DRAG
mice was a consequence of poor differentiation of hu-
man HSC toward the erythrocytic lineage. This was clear
since bone marrow of DRAG mice contained low num-
bers of human erythrocytic precursors (CD45−CD235+)
and the human erythrocytic precursors were not undergo-
ing apoptosis. Previous studies in NSG mice (that unlike
DRAG mice do not express human HLA II molecules)
have led to controversial results on their ability to generate
human RBCs [41,42]. As found in this study, DRAG mice
developed human erythrocytes and reticulocytes for several
months upon the infusion of the human HSCs, albeit at
low numbers. Approaches that increase the endogenous
levels of human RBCs in DRAG mice are expected to
increase the levels of parasitaemia and would add more
value for this new P. falciparum mouse model.
DRAG mice sustained P. falciparum blood stage
parasitaemia for a limited period of time since all mice
self-cured by days 30–45 after the challenge with
sporozoites. The ability of DRAG mice to clear the
infection was associated with development of antibodies
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http://www.malariajournal.com/content/13/1/386(human IgM and IgG) and TNF-mediated CD4 and
CD8 T cell responses to the blood stage parasites. Nu-
merous studies in humans and rodent malaria models
indicated that high level parasitaemia induces immuno-
suppression by dendritic cell dysfunction and stimula-
tion of regulatory T cells [13,43,44], and studies have
shown that maintaining low level blood stage parasit-
aemia by chloroquine treatment allows development of
protective immune responses to the blood stage para-
sites [13,45]. Since DRAG mice develop a functional hu-
man immune system [21], the low level parasitaemia
may thus account for the ability of DRAG mice to elicit
specific immune responses and to clear parasites from
the blood.
Considering that erythrocytes do not express HLA
molecules [46] and infected erythrocytes cannot be dir-
ectly eliminated by CD4 and CD8 T cells in a HLA-
restricted manner, antibodies and factors secreted by im-
mune cells are thought to be responsible for clearance of
malaria parasites from the blood. Antibodies contribute
to parasite clearance by several mechanisms such as (i)
neutralization of proteins required for parasite invasion
of erythrocytes, (ii) activation of complement cascade,
(iii) Fc receptor mediated phagocytosis and (iv) Fc-
receptor-mediated lysis by NK and NKT cells (ADCC,
antibody-dependent cell cytotoxicity) [1]. Cellular im-
munity further contributes to clearance of blood stage
parasites by secretion of cytokines, such as TNF, and
toxic NO molecules [43,44]. DRAG mice elicited both
antibodies and TNF-mediated responses to P. falcip-
arum blood stage parasites. The role of antibodies in
clearing blood stage parasites in DRAG mice is further
supported by the fact that human monoclonal antibodies
generated using human B cells from infected DRAG
mice showed strong anti-parasitic activity in vitro
(Wijayalath et al., manuscript in preparation). However,
some DRAG mice (4 out of 18 tested) did not have de-
tectable specific antibodies as measured by IFA, which
further suggests that cellular-mediated responses also
contributed to clearance of P. falciparum parasites from
the blood. The beneficial role of TNF in malaria has
been demonstrated in animals treated with neutralizing
TNF monoclonal antibodies, which prevented clearance
of parasitaemia [47]. Though DRAG mice are deficient
in mouse innate immunity (i.e., NK and dendritic cells)
due to the IL2Rgc KO mutation [48,49], DRAG mice de-
velop mouse monocytes that could have also contributed
to the clearance of P. falciparum blood stage parasites.
In aggregate, this study provides first evidence for a
new human-immune-system mouse model sustaining
the complete vertebrate life cycle of P. falciparum. The
proven ability of DRAG mice to develop a functional
human immune system and to elicit specific responses
to P. falciparum parasites may aid to decipher immunecorrelates of protection and identification of protective
malaria antigens.
Conclusions
This study provides first evidence for a humanized
mouse model that sustains the complex life cycle of P.
falciparum malaria (liver-to-blood stages of infection
and transmission to mosquito) without the need of
exogenous administration of human hepatocytes/
erythrocytes or P. falciparum parasite adaptation. This
study also demonstrated that DRAG mice elicit human
antibody and cellular responses to P. falciparum blood
stage parasites which may further help for discovery of
protective malaria antigens and to decipher immune
correlates of protection. Experimental approaches that
can successfully increase the levels of endogenously-
produced human erythrocytes and parasitaemia in
DRAG mice are expected to add more value to this
new P. falciparum mouse model.
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